The Oncology Institute, Inc. (NASDAQ:TOI – Get Rating)’s share price shot up 1.3% on Wednesday . The company traded as high as $0.48 and last traded at $0.43. 468,333 shares changed hands during trading, an increase of 187% from the average session volume of 163,166 shares. The stock had previously closed at $0.42.
Analysts Set New Price Targets
Separately, Guggenheim decreased their price target on shares of Oncology Institute from $6.00 to $3.00 in a research report on Monday, March 20th.
Oncology Institute Stock Performance
The company has a quick ratio of 3.61, a current ratio of 3.95 and a debt-to-equity ratio of 0.83. The business’s fifty day simple moving average is $0.57 and its 200-day simple moving average is $1.18.
Insider Transactions at Oncology Institute
In related news, Director Richard A. Barasch acquired 50,000 shares of the stock in a transaction on Friday, March 17th. The stock was bought at an average cost of $0.55 per share, with a total value of $27,500.00. Following the transaction, the director now directly owns 257,193 shares in the company, valued at $141,456.15. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 10.40% of the company’s stock.
Institutional Investors Weigh In On Oncology Institute
Hedge funds have recently modified their holdings of the business. Susquehanna International Group LLP bought a new position in shares of Oncology Institute during the 1st quarter worth approximately $30,000. Morgan Stanley increased its stake in shares of Oncology Institute by 1,192.2% in the fourth quarter. Morgan Stanley now owns 18,414 shares of the company’s stock worth $30,000 after acquiring an additional 16,989 shares during the period. Jane Street Group LLC purchased a new stake in Oncology Institute during the first quarter worth $32,000. American International Group Inc. purchased a new stake in Oncology Institute during the second quarter worth $44,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in Oncology Institute during the third quarter worth $50,000. Hedge funds and other institutional investors own 70.45% of the company’s stock.
About Oncology Institute
The Oncology Institute, Inc, an oncology company, provides medical oncology services in the United States. Its services include physician services, in-house infusion and dispensary, clinical trial services, radiation, outpatient stem cell transplants and transfusions programs, and patient support. The company also offers and manages clinical trial services, such as managing clinical trials, palliative care programs, and stem cell transplants services.
- Get a free copy of the StockNews.com research report on Oncology Institute (TOI)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Oncology Institute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncology Institute and related companies with MarketBeat.com's FREE daily email newsletter.